Evidence map›Paper›PMID 32670558›Full record

ArticleToxicology research2020

An androgen-independent mechanism underlying the androgenic effects of 3-methylcholanthrene, a potent aryl hydrocarbon receptor agonist.

Noriko Sanada, Yuka Gotoh-Kinoshita, Naoya Yamashita, Ryoichi Kizu

Open access · bronzeAbstract read
In one paragraph

Article in Toxicology research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact, top 93% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Noriko SanadaFaculty of Pharmaceutical Sciences, Doshisha Women's College of Liberal Arts; Kodo, Kyotanabe 610-0395, Kyoto, Japan.
Yuka Gotoh-KinoshitaFaculty of Pharmaceutical Sciences, Doshisha Women's College of Liberal Arts; Kodo, Kyotanabe 610-0395, Kyoto, Japan.
Naoya YamashitaFaculty of Pharmaceutical Sciences, Doshisha Women's College of Liberal Arts; Kodo, Kyotanabe 610-0395, Kyoto, Japan.
Ryoichi KizuFaculty of Pharmaceutical Sciences, Doshisha Women's College of Liberal Arts; Kodo, Kyotanabe 610-0395, Kyoto, Japan.
Doshisha Women's College of Liberal Arts · JPKyocera (Japan) · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Aryl hydrocarbon receptor (AhR) and androgen receptor (AR) are ligand-activated transcription factors with profound cross-talk between their signal transduction pathways. Previous studies have shown that AhR agonists activate the transcription of AR-regulated genes in an androgen-independent manner; however, the underlying mechanism remains unclear. To decipher this mechanism, we evaluated the effects of 3-methylcholanthrene (3MC), a potent AhR agonist, on the transcription of AR-regulated genes in three AR-expressing cell lines. 3MC induced the expression of not only three representative AR-regulated chromosomal genes but also the exogenous AR-responsive luciferase reporter gene. No significant difference in the 3MC-induced luciferase activity was detected in the presence of SKF-525A, a non-specific inhibitor of CYP enzymes. The androgenic effects of 3MC were diminished by AhR and AR knockdown. Following 3MC treatment, the amount of nuclear AhR and AR increased synchronously. Co-immunoprecipitation revealed that AhR and AR formed a complex in the nucleus of cells treated with 3MC. AR was recruited to the proximal promoter and distal enhancer regions of the

Indexed as

3-methylcholanthreneandrogenic effectandrogen receptoraryl hydrocarbon receptorcross-talk

Identifiers

PMID32670558
PMCPMC7329177
OpenAlexW3039849025

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.